ARTIVION, INC.
For the period ended May 18, 2026. Filed May 18, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 18, 2026 · Filed May 18, 2026
Use the contents to explore the available documents and sections.
Contents
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements for the purposes of federal and state securities laws. These forward-looking statements involve risks and uncertainties that could significantly affect the financial or operating results of Artivion. Forward-looking statements in this Current Report on Form 8-K include, among other things, statements regarding the contingent consideration that may become payable based on the future performance of Endospan’s NEXUS™ product, including the timing and amount of any such payment. These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among other things, risks related to Artivion’s ability to successfully integrate Endospan’s operations and technology, the future performance of Endospan’s NEXUS™ product, and other risks and uncertainties, including but not limited to those described in Artivion’s Annual Report on Form 10-K on file with the SEC and from time to time in other reports including Artivion’s Quarterly Reports on Form 10-Q. Artivion disclaims any obligation or duty to update or modify any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit Number | Description |
| 10.1+^ | Securities Purchase Option Agreement, dated as of September 11, 2019, by and among CryoLife, Inc., Endospan Ltd., the securityholders of Endospan listed on Schedule 1 thereto (together with any additional securityholder that becomes a party by joinder) and Shareholder Representative Services LLC, as the Securityholder representative (incorporated by reference to Exhibit 10.1 to Artivion’s Current Report on Form 8-K filed on May 7, 2026). |
| 10.2^ | Amendment No. 1 to Securities Purchase Option Agreement, dated July 1, 2024, by and among Artivion, Inc., Endospan Ltd. and Shareholder Representative Services LLC, as the securityholder representative (incorporated by reference to Exhibit 10.2 to Artivion’s Current Report on Form 8-K filed on May 7, 2026). |
| 10.3^ | Amendment No. 2 to Securities Purchase Option Agreement, dated January 9, 2026, by and among Artivion, Inc., Endospan Ltd. and Shareholder Representative Services LLC, as the securityholder representative (incorporated by reference to Exhibit 10.3 to Artivion’s Current Report on Form 8-K filed on May 7, 2026). |
| 99.1* | Press Release dated May 18, 2026. |
| 104 | Cover Page Interactive Data File (the Cover Page Interactive Data File is embedded within the Inline XBRL document). |
| * | Furnished herewith. |
|---|---|
| + | Schedules or similar attachments have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish a copy of any omitted schedule to the Securities and Exchange Commission upon request. |
| ^ | Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. |
-3-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.